Overview

Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Status:
Completed
Trial end date:
2018-11-02
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of multiple dose levels of NYX-2925 versus placebo in treating the neuropathic pain associated with Diabetic Peripheral Neuropathy.
Phase:
Phase 2
Details
Lead Sponsor:
Aptinyx
Collaborators:
inVentiv Health Clinical
Syneos Health